Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results. Jackson GH et al. Br J Haematol. 2014 Mar 27. doi: 10.1111/bjh.12861. [Epub ahead of print]. Carfilzomib-related acute kidney injury may be prevented by N-acetyl-L-cysteine. Wanchoo R et al. J Oncol Pharm Pract. 2014…
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.Mateos MV et al. Haematologica. 2014 Apr 24. [Epub ahead of print].Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study.Ahn SY et…
Survival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation. A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma and the European Myeloma Network. Ozaki S et al. Acta Haematol. 2014 Mar 22;132(2):211-219. [Epub ahead of print]. Pathways for blood and bowel cancer patients…
Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation.
Nooka AK et al. Biol Blood Marrow Transplant. 2014 Mar 6. pii: S1083-8791(14)00148-7. doi: 10.1016/j.bbmt.2014.02.025. [Epub ahead of print].
Plasma Exchange for Kidney Disease: What Is the Best Evidence?
Hildebrand AM et al. Adv Chronic Kidney Dis. 2014 Mar;21(2):217-227. doi: 10.1053/j.ackd.2014.01.008.
Rapid Progression of Anemia Related to Tumor-lysis Syndrome Associated with Bortezomib Treatment in Myeloma Patients. Suzuki K et al. Jpn J Clin Oncol. 2014 Mar 23. [Epub ahead of print]. Prediction of presence of kidney disease in a general patient population undergoing intravenous iodinated contrast enhanced computed tomography. Moos SI et al. Eur Radiol. 2014…
Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation.Fouquet G et al. J Cancer. 2014 Mar 11;5(3):248-52. doi: 10.7150/jca.8541. eCollection 2014Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.Mark TM et al. Leuk Lymphoma. 2014 Mar 25. [Epub ahead of…
The Pharmacokinetics and Pharmacodynamics of Denosumab in Patients with Advanced Solid Tumours and Bone Metastases: A Systematic Review. Sohn W et al. Br J Clin Pharmacol. 2014 Feb 18. doi: 10.1111/bcp.12355. [Epub ahead of print]. Efficacy of cryotherapy associated with laser therapy for decreasing severity of melphalan-induced oral mucositis during hematological stem-cell transplantation: a prospective…
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Dimopoulos MA et al. Leukemia. 2014 Feb 5. doi: 10.1038/leu.2014.60. [Epub ahead of print]. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Engelhardt M et al. Haematologica. 2014 Feb;99(2):232-42. doi: 10.3324/haematol.2013.099358.…
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Palumbo A et al. Lancet Oncol. 2014 Feb 10. pii: S1470-2045(13)70609-0. doi: 10.1016/S1470-2045(13)70609-0. [Epub ahead of print]. Lenalidomide and second malignancies in myeloma patients. Pratt G. Lancet Oncol. 2014 Feb 10. pii: S1470-2045(14)70001-4. doi: 10.1016/S1470-2045(14)70001-4. [Epub ahead of print].…
Subcutaneous Bortezomib incorporated into the Bortezomib-Thalidomide-Dexamethasone regimen as part of frontline therapy in the context of autologous stem-cell transplantation for multiple myeloma.
Lok A et al. Haematologica. 2014 Feb 14. [Epub ahead of print]